Brief: Marksans Pharma Gets Communication From USFDA On Verification Of NDMA In Metformin Extended Release Tablets
01/06/2020 04:24
June 1 (Reuters) - Marksans Pharma Ltd MARK.NS :
* GOT COMMUNICATION FROM USFDA ON VERIFICATION OF NDMA IN
METFORMIN EXTENDED RELEASE TABLETS
* SUBMITTED PRELIMINARY RESPONSE TO USFDA, FURTHER
COMMUNICATING
WITH THEM
* FOR YEAR ENDED MARCH 31, EXPORTS TO USA FOR METFORMIN
EXTENDED
RELEASE TABLETS WAS LESS THAN 1% OF CONSOL REVENUE
Source text for Eikon: ID:nBSE6Cw8cC
Further company coverage: MARK.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marksans Pharma
See all newsIndia's Marksans Pharma jumps to over 18-month high after more than doubling quarterly profit
Brief: Marksans Pharma Ltd To Acquire 100% Of Netherlands-Based Qliniq B.V
India's Marksans Pharma jumps to 10-month high after Q4 profit rise
Brief: Marksans Pharma March-Quarter Consol Net Profit 1.48 Billion Rupees
Brief: Marksans Pharma Ltd Receives USFDA Approval For Benzonatate Capsules USP, 100 Mg & 200 Mg